0.16
0.16 (0%)
As of Apr 17, 2025
In8bio, Inc. [INAB]
Source:
Company Overview
In8bio, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | ( 646 ) 600-6438 |
| Industry | manufacturing |
| CEO | William Ho |
| Website | www.in8bio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-30.3 |
| Net Income | $-30 |
| Net Cash | $3.1 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -89.9% |
| Profit as % of Stockholder Equity | -120.3% |
Management Effectiveness
| Return on Equity | -120.3% |
| Return on Assets | -89% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $33.7 |
| Total Liabilities | $8.8 |
| Operating Cash Flow | $-23.3 |
| Investing Cash Flow | $-0.6 |
| Financing Cash Flow | $27 |
